×
Don't Miss Out!
Get your weekly Breakfast Briefing eNewsletter, filled with news, trends, and vital information from DIA!
Back to Agenda
Unintended Consequences: Effects of Inflation Reduction Act on the Future of Pharmaceutical Innovation
Session Chair(s)
Sarah K Martin, PhD, MS
Senior Director - Global Regulatory Policy (Oncology)
Eli Lilly & Co., United States
Among the largest areas of concern with the Inflation Reduction Act (IRA) are potential unintended consequences to pharmaceutical innovation. This forum will convene industry experts to explore the impact of and potential adjustments to the IRA.
Learning Objective : Discuss the unintended consequences of the IRA on innovation; Examine potential legislative solutions.
Speaker(s)
Panelist
Representative Invited
Eli Lilly and Company, United States
Industry Perspective
Ryan Gough
Woodberry Associates and PACH, United States
Partner, Senior Vice President, Public Affairs
The Impacts of the Inflation Reduction Act on Biopharmaceutical Investment Decisions
Richard Xie, PhD
RA Capital, United States
Senior Health Economist
Early Signals of IRA Impact: Theoretical and Observed Unintended Consequences
Julie Ann Patterson, PharmD, PhD
National Pharmaceutical Council, United States
Senior Director of Research
Have an account?